Equity Overview
Price & Market Data
Price: $2.29
Daily Change: +$0.03 / 1.31%
Daily Range: $2.29 - $2.31
Market Cap: $406,173,408
Daily Volume: 860
Performance Metrics
1 Week: 11.33%
1 Month: -11.72%
3 Months: 127.3%
6 Months: 340.3%
1 Year: 448.4%
YTD: 127.2%
Company Details
Employees: 78
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.